

Premier Biomedical Inc. Fact Sheet.

- Premier Biomedical (PBI) is a publicly traded research-based company that intends to discover and develop medical treatments targeting the treatment of heretofore incurable and/or hard-to-cure diseases.
- The Company's proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects.
 - Superior to current treatments which eliminate the presence of most illnesses but often with catastrophic or even fatal side effects.
 - Subtractive therapy (removal of harmful molecules) reduces risks associated with conventional "Additive" therapy (adding chemicals to the body).
 - Targets Cancer, Leukemia, Cockayne Syndrome, Neurofibromatosis, Fibromyalgia, Multiple Sclerosis, and Atherosclerosis – collectively over \$700 billion market opportunity.
- Developed a proprietary patented drug candidate, *Feldetrex*[™] as a potential treatment for Fibromyalgia, neuropathic pain, and chemical addiction.
 - Expected to deliver significant relief to patients, while presenting fewer side effects than other alternate medications.
 - The annual market size of all proposed market segments for *Feldetrex*[™] is over \$20 billion.
 - The company strategy is to use the sales of *Feldetrex*[™] to provide short term revenue and to fund technology.
- Penn Biomedical Group (PBG) study analyzed potential market for *Feldetrex* versus entrenched competition, Lyrica and Cymbalta, whose sales exceed \$10B currently.
- The Company has established two outstanding research partnerships with the University of Texas, El Paso (UTEP) and the Department of Defense
 - Leverage the substantial infrastructure and resourced capacity of these organizations to perform experimentation and to engage in product development in an inexpensive and efficient manner.
 - UTEP contractually owns 10% of PBI profits associated with their direct participation programs. The DoD contractually can receive medications at PBI cost.
 - Superior results in animal testing of proprietary immunotherapy cancer antibody treatments targeting cancer antigens CTLA-4, PD-1, and BTLA protein activities.
- A second PBG study examined anti-cancer drug potential sales, indicating a potential revenue of \$1.9 B.
- In order to establish short term revenue to finance on-going research, the Company has initiated efforts to establish Joint Ventures with established pharmaceutical firms in South America & Asia to develop, manufacture and distribute Premier Biomedical's treatments and drugs. Press releases announcing these joint ventures will be issued shortly.
- An outside healthcare market advisor in Brazil forecasted potential sales of PBI products in South America of \$400M per year by 2020.

- In conjunction with UTEP, the company is in the process of contracting a post-doctoral candidate to prepare and submit grant requests in support of our combined research and development.
- Strong management team and advisors with extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.